Investors seem to have a gut feeling about microbiome platform DayTwo’s growth potential. The Israel-based startup, which offers a glycemic control solution for people with type 2 diabetes, announced this week that it has secured $31 million in Series B financing.
- Founded: 2015
- Headquarters: Tel Aviv, Israel
- Funding: $53M
- Industry: Healthtech
DayTwo will use the funding to accelerate go-to-market initiatives in the United States to grow partnerships with payers, providers and employers. The company also plans to develop more products and services for metabolic and gastrointestinal conditions.
Ofek Ventures and aMoon co-led the round, which also saw participation from existing investors Seventure Partners and Johnson & Johnson continued their participation in the round. DayTwo's total funding now stands at $48 million.
"DayTwo is the only evidence-based, actionable, microbiome platform in the market today. We are in a privileged position to leverage our experience including first-rate science, clinical trials in Israel and the United States, tens of thousands of customers, and provider, employer, and payer relationships."
"DayTwo is the only evidence-based, actionable, microbiome platform in the market today. We are in a privileged position to leverage our experience including first-rate science, clinical trials in Israel and the United States, tens of thousands of customers, and provider, employer, and payer relationships," said Lihi Segal, CEO and Founder of DayTwo. " This deep and broad foundation, coupled with this financing, enables DayTwo to address the large and pressing clinical need to bring food-as-medicine to market for people with type 2 diabetes in the United States."
By using gut profiling and other clinical parameters, DayTwo enables users to adopt a food-as-medicine approach to manage glycemic levels. The precision medicine platform can deliver personalized dietary interventions based on their microbiome, which impacts their metabolic rate and, therefore, blood sugar levels.
"Digital health solutions such as DayTwo's accelerate treatment, disease prevention, and management of chronic illnesses," remarked Yair Schindel, M.D., M.B.A., and Managing Partner aMoon Fund. "The company's ability to make precision medicine accessible through their glycemic-control solution is helping people with diabetes today; I feel fortunate to witness this as the company expands to the United States."